scholarly journals Tedizolid Activity Against Clinical Mycobacterium abscessus Complex Isolates—An in vitro Characterization Study

2018 ◽  
Vol 9 ◽  
Author(s):  
Ying Wei Tang ◽  
Bernadette Cheng ◽  
Siang Fei Yeoh ◽  
Raymond T. P. Lin ◽  
Jeanette W. P. Teo
Keyword(s):  
Mycobacterium Abscessus ◽  
Mycobacterium Abscessus Complex ◽  
In Vitro Characterization ◽  
Characterization Study

scholarly journals 1350. Clofazimine as an Oral Companion Drug for Treatment of Mycobacterium abscessus complex Infections

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S488-S489
Author(s):  
Joy Yong ◽  
Ka Lip Chew ◽  
Paul Tambyah
Keyword(s):  
Active Agent ◽  
Liver Function Tests ◽  
Mycobacterium Abscessus ◽  
Prolonged Treatment ◽  
Attractive Alternative ◽  
In Vitro Susceptibility ◽  
Treatment Regimens ◽  
Drug Intolerance ◽  
Mycobacterium Abscessus Complex

Abstract Background Infections caused by the multi-drug-resistant Mycobacterium abscessus complex (MabsC) are challenging to treat and often require multiple antimicrobials for a prolonged treatment course and still have poor outcomes. Clofazimine, an oral anti-leprosy drug, has demonstrated good in vitro susceptibility and is being increasingly employed in treatment regimens for MabsC infections. We performed a drug-use-evaluation of clofazimine in the treatment of MabsC infections. Methods A retrospective review was performed for all patients with MabsC infections treated with clofazimine-containing regimens from January 2014 to June 2017. Results Twenty-nine patients were included. Twelve patients had pulmonary MabsC infections and seventeen had extrapulmonary infections. All isolates had clofazimine minimum-inhibitory-concentration of ≤0.5 mg/L as tested by broth microdilution. Clofazimine was prescribed at initiation of therapy in 31.0% (9/29), as a companion drug during maintenance therapy after initial intravenous therapy in 44.8% (13/29) and as part of salvage therapy due to disease progression or drug intolerance in 24.1% (7/29) of patients. Dosing of clofazimine for the pediatric patients was prescribed at 1–2 mg/kg/day while the adult patients received a range of 50–200 mg/day. Clofazimine was given for a median duration of 148.5 days (range: 14–1212) and most commonly in combination with clarithromycin (82.8%), amikacin (58.6%), and cefoxitin (24.1%). Twelve patients had documented adverse reactions attributable to clofazimine: skin hyperpigmentation (66.7%), abnormal liver function tests (16.7%), and gastrointestinal disturbance (16.7%). Table 1 describes the patients who had clofazimine ceased due to an adverse effect. Nine patients with pulmonary MabsC infections and 16 with extrapulmonary MabsC infections had documented improvement in symptoms. Conclusion Clofazimine as a companion drug in the treatment of MabsC infections was reasonably tolerated over a prolonged period of time. Its availability as an oral active agent makes it an attractive alternative to IV companion drugs and potentially improves compliance to the protracted treatment courses for patients with MabsC infections. Disclosures All authors: No reported disclosures.

In vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens

2020 ◽  
Author(s):  
Ka Lip Chew ◽  
Sophie Octavia ◽  
Joelle Go ◽  
Sally Ng ◽  
Yit Er Tang ◽  
...  
Keyword(s):  
Retrospective Review ◽  
Susceptibility Testing ◽  
Mycobacterium Abscessus ◽  
In Vitro Activity ◽  
Broth Microdilution ◽  
In Vitro Susceptibility ◽  
Treatment Regimens ◽  
Mycobacterium Abscessus Complex ◽  
Additional Testing

Abstract Objectives To determine the in vitro susceptibility of members of the Mycobacterium abscessus complex to routinely tested antibiotics and to an extended antibiotic panel. Methods Non-duplicate isolates for which susceptibility testing results were available were included in this study. Retrospective laboratory records were reviewed, including tigecycline susceptibility results, and testing was performed with additional drugs, including vancomycin, dalbavancin, telavancin, oritavancin, rifabutin, delafloxacin, eravacycline, clofazimine and bedaquiline using broth microdilution (Sensititre, Thermo Fisher). Results A total of 218 M. abscessus complex isolates were included for retrospective review, of which 151 were respiratory isolates. Of these 218 isolates, 211 were available for additional testing with the extended antibiotic panel. Of these, 146 were respiratory isolates. One isolate had a vancomycin MIC of 2 mg/L and MICs of all other isolates were >8 mg/L. All isolates had MICs of >8 mg/L for oritavancin, dalbavancin and telavancin. One isolate had a delafloxacin MIC of 4 mg/L and MICs of all other isolates were >8 mg/L. The MIC50/MIC90s of rifabutin, tigecycline, eravacycline, clofazimine and bedaquiline were 16/32, 0.5/1, 0.12/0.25, 0.12/0.25 and 0.06/0.12 mg/L, respectively. Conclusions In vitro activity was demonstrated for clofazimine, bedaquiline and eravacycline, indicating potential for inclusion as standardized therapy for M. abscessus complex infections.

scholarly journals Evaluation of Ceftaroline-Avibactam Activity in vitro and ex vivo Against Mycobacterium abscessus Complex

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S675-S675 ◽  
Author(s):  
Ruchi Pandey ◽  
Liang Chen ◽  
Elena Shashkina ◽  
Claudia Manca ◽  
Robert A Bonomo ◽  
...  
Keyword(s):  
Ex Vivo ◽  
Mycobacterium Abscessus ◽  
Mycobacterium Abscessus Complex

An in vitro characterization study of new near infrared dyes for molecular imaging

2009 ◽  
Vol 44 (9) ◽  
pp. 3496-3503 ◽  
Author(s):  
Jutta Pauli ◽  
Tibor Vag ◽  
Romy Haag ◽  
Monika Spieles ◽  
Matthias Wenzel ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Near Infrared ◽  
In Vitro Characterization ◽  
Characterization Study

scholarly journals In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex

2014 ◽  
Vol 20 (5) ◽  
pp. O297-O300 ◽  
Author(s):  
M. Lavollay ◽  
V. Dubée ◽  
B. Heym ◽  
J.-L. Herrmann ◽  
J.-L. Gaillard ◽  
...  
Keyword(s):  
Mycobacterium Abscessus ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Mycobacterium Abscessus Complex

scholarly journals In vitro efficacy of relebactam versus avibactam against Mycobacterium abscessus complex

2021 ◽  
pp. 100064
Author(s):  
James Harrison ◽  
John A. Weaver ◽  
Maya Desai ◽  
Jonathan A.G. Cox
Keyword(s):  
Mycobacterium Abscessus ◽  
Mycobacterium Abscessus Complex

In vitro characterization study of Bacillus mojavensis KJS-3 for a potential probiotic

2011 ◽  
Vol 20 (4) ◽  
pp. 1155-1159 ◽  
Author(s):  
Kang Min Kim ◽  
Tae Sung Jung ◽  
Seon Ok ◽  
Chan Young Ko ◽  
Jae Seon Kang
Keyword(s):  
Bacillus Mojavensis ◽  
In Vitro Characterization ◽  
Characterization Study

scholarly journals New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates

2019 ◽  
Vol 63 (9) ◽  
Author(s):  
Amit Kaushik ◽  
Nicole C. Ammerman ◽  
Nicole M. Parrish ◽  
Eric L. Nuermberger
Keyword(s):  
Mycobacterium Abscessus ◽  
Clinical Development ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Content Type ◽  
Mycobacterium Abscessus Complex

ABSTRACT The new diazabicyclooctane-based β-lactamase inhibitors avibactam and relebactam improve the in vitro activity of β-lactam antibiotics against bacteria of the Mycobacterium abscessus complex (MABC). Here, we evaluated the in vitro activities of two newer diazabicyclooctane-based β-lactamase inhibitors in clinical development, nacubactam and zidebactam, with β-lactams against clinical isolates of MABC. Both inhibitors lowered the MICs of their partner β-lactams, meropenem (8-fold) and cefepime (2-fold), respectively, and those of other β-lactams, similar to prior results with avibactam and relebactam.

Sign in / Sign up

Export Citation Format

Share Document